Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland.

Andrea Favre-Bulle Goran Bencina Shujing Zhang Ruixuan Jiang Daniel Andritschke Arjun Bhadhuri

Published in: Journal of medical economics (2023)

The model demonstrated that pembrolizumab is highly cost-effective versus observation in patients with resected stage IIB/IIC melanoma in Switzerland. The ICER was below the WTP threshold of CHF 100,000, commonly used for cost-effectiveness models in Switzerland.

Keyphrases

lymph node
advanced non small cell lung cancer
early stage
replacement therapy
smoking cessation